RGEN

Repligen Corp. 10-Q Summary: Quarter Ended December 31, 1996

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 1996, and the nine-month period ended on that date for Repligen Corporation. The company is a biotechnology firm focused on drug discovery technologies and therapies for inflammation and immunosuppression. During the prior fiscal year (ended March 31, 1996), Repligen completed a major restructuring, including workforce reductions, termination of research programs, and the closure of its Cambridge facility, relocating operations to Needham, Massachusetts.

Key Financial Metrics

Cash Flow (Nine Months Ended Dec 31, 1996): Net cash used in operating activities was $3,299,086. Net cash used in investing activities was $327,882. There was no cash provided by financing activities.

Material Changes Versus Prior Period

• Revenue Decline: Total revenues decreased approximately 49% for the three-month period and 71% for the nine-month period compared to the prior year. This was primarily driven by a loss of significant research and development contract revenues from Eli Lilly and Company and Repligen Clinical Partners, L.P.
• Expense Reduction: Total expenses decreased 73% for the quarter and 80% for the nine-month period compared to the prior year. This reflects the successful implementation of the fiscal 1996 restructuring, including lower headcount and facility costs following the move to Needham.
• Product Sales: Product revenues increased 197% for the quarter ($503,049 vs. $169,289) but decreased 27% for the nine-month period ($1,123,827 vs. $1,543,026). The nine-month decrease is attributed to the discontinuance of contract manufacturing, partially offset by increased Protein A product line sales.
• Liquidity: Cash, cash equivalents, and marketable securities decreased by 52% (from $7,222,000 to $3,458,000) since March 31, 1996, due to net losses and the payment of accrued restructuring expenses.

Guidance, Outlook, and Unusual Items

Unusual Items: The company recorded a non-recurring charge of $365,285 for purchased research and development. This expense relates to the acquisition of additional preferred shares and warrants of its subsidiary, ProsCure Inc., increasing Repligen's ownership interest from 63% to 90%. The technology acquired requires further development and was expensed immediately.

Outlook and Liquidity: Management believes current cash equivalents and marketable securities are sufficient to satisfy working capital and capital expenditure requirements for the next twelve months. However, the company notes that future expansion is dependent on increased product sales, future financing, or new partnerships. There is no assurance that additional financing will be available on favorable terms if needed.

Risks: Future results depend on the ability to meet liquidity needs, implement growth strategies, and respond to changing technologies. The company faces competition from entities with greater financial resources.

Investor Verification Checklist

• Cash Runway: Verify if the current cash balance of ~$3.3 million is sufficient to sustain operations for the projected 12-month period given the continued net losses.
• Revenue Concentration: Assess the impact of the loss of Eli Lilly and Partnership contracts on future R&D revenue stability.
• Restructuring Completion: Confirm that all accrued restructuring liabilities (severance, lease settlements) have been fully paid and no further charges are anticipated.
• ProsCure Acquisition: Evaluate the strategic value and development timeline of the ProsCure cancer drug discovery technologies acquired in the quarter.
• Product Mix: Monitor the growth trajectory of the Protein A product line to ensure it can offset the loss of contract manufacturing revenue.